Challenges and opportunities in the development of complex generic long-acting injectable drug products.
Long-acting injectable (LAI) drug products enable the controlled release of a drug over an extended duration of time to improve the therapeutic effect, safety profile, or administration of an injectable product. The development of generic [505(j)] and differentiated [505(b)(2)] LAI products helps to provide patients and healthcare providers with more treatment options and to reduce overall healthcare costs, including those associated with drug product administration and patient compliance. In this review, we analyze the landscape of LAI products and identify the most common technical challenges that potential generic product entrants face. We focus on five formulation technologies that account for ~90% of approved LAI products, including those eligible for generic product registration over the next five years, to illustrate technology-specific challenges. We then review efforts from the U.S. Food and Drug Administration (FDA) to promote more generic product competition and emphasize the importance of collaboration among government, industry, and academia to advance the knowledge and capabilities of the scientific community. Regulatory bodies, industry, and academia are encouraged to anticipate challenges with emerging innovative LAI technologies and to leverage the experiences built on established technologies to foster generic product development.
["O'Brien|Matthew N|MN|", 'Jiang|Wenlei|W|', 'Wang|Yan|Y|', 'Loffredo|David M|DM|']
D016568:Drugs, Generic D006801:Humans D007267:Injections D014481:United States D014486:United States Food and Drug Administration
Generics Long-acting injectable Controlled release Complex generic products Depot Drug delivery